Europe extends Darzalex approval as multiple myeloma treatment
The European Commission has extended its approval of Johnson & Johnson’s Darzalex (daratumumab) for injection under the skin as part of a quadruple regimen…
Myeloma
Exercise program boosts life quality in newly diagnosed patients: Trial
Getting regular exercise can help improve life quality, ease depression, and minimize the risk of medication side effects in people with newly diagnosed multiple…
CAR T-cell therapy successfully treats myeloma in Hong Kong
A CAR T-cell therapy manufactured in mainland China has been successfully deployed for the first time in Hong Kong to treat a man with myeloma,…
Personalized cancer vaccine shows potential in myeloma, solid tumors
A personalized cancer vaccine called PGV001 showed potential in combating several types of cancer, both solid tumors and blood malignancies like myeloma, in a…
2nd Iceland Cycling Expedition aims to raise myeloma research funds
The International Myeloma Foundation (IMF) has announced its 2nd annual Iceland Cycling Expedition (ICE), a seven-day endurance bike ride to raise funds for…
Use of dexamethasone may manage Tecvayli’s immune side effect: Study
The use of dexamethasone alone may successfully treat the immune side effect cytokine release syndrome (CRS) in people with relapsed or refractory multiple…
March’s Myeloma Action Month means sharing patient milestones
This year’s Myeloma Action Month (MAM), which is observed each March, is focused on celebrating and sharing patient milestones to help call…
High-risk genetic changes with myeloma tied to poorer outcomes
The presence of more than one high-risk genetic abnormality is associated with dramatically more aggressive multiple myeloma, a study reported. Its findings highlight the…
FDA decision on linvoseltamab in treating RRMM expected in July
The U.S. Food and Drug Administration (FDA) has agreed to review an application from Regeneron Pharmaceuticals seeking the approval of linvoseltamab to treat…
Complete response to CAR T-cell therapy reported in RRMM patient
A first patient with relapsed/refractory multiple myeloma (RRMM) treated with CT0590, Carsgen Therapeutics’ CAR T-cell therapy, showed a complete response to the…
